NYSE:NVO

Novo-Nordisk (NVO)

43.19
+1.48 (3.55%)
as of Sep 17, 2026, 8:00:00 pm Market Open.
267 watching
0
BUY
Past Top pick. Insulin demain is growing over the next 20 years. It's still a long term investment.
TOP PICK
Manufactures insulin. Human insulin is in huge demand and they control the market. Good earnings last quarter. Good price.
TOP PICK
The growth in cases of diabetes in the next 20 years is expected to double from 3 to 6 hundred million globally. The stock had fallen from $58 to the low $50's because their drug was going to be delayed. Stock is now getting interesting.
PAST TOP PICK
(A top pick Dec 1/03. Up 30%.) The cases of diabetics is expected to double.
TOP PICK
In pharmaceuticals, they devote most money per revenue into R&D. Demographically, feels that China and India will be strong future markets.
TOP PICK
Takeover target. Diabetes is growing. Expects 10/15% growth over time.
BUY
Great company. Will do well.
TOP PICK
Trading at FMV. 33% growth in diabetes.
TOP PICK
Just split. Growing 40% in sales. Growth is in the 30/40% range.
BUY
Bullet proof portfolio-mid caps (35%)
TOP PICK
Good earnings. Growing at 50% a year.
BUY
Held their own in market drop. Good price now
Showing 196 to 207 of 207 entries